Halozyme Therapeutics Stock Today
| HALO Stock | USD 38.97 0.26 0.67% |
Performance9 of 100
| Odds Of DistressLess than 1
|
Halozyme Therapeutics is selling at 38.97 as of the 24th of April 2024; that is 0.67 percent up since the beginning of the trading day. The stock's open price was 38.71. Halozyme Therapeutics has a very small chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Halozyme Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of January 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of March 2004 | Category Healthcare | Classification Health Care |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California. Halozyme Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 127.05 M outstanding shares of which 7.89 M shares are currently shorted by private and institutional investors with about 8.17 trading days to cover. More on Halozyme Therapeutics
Moving together with Halozyme Stock
| 0.81 | OPT | Opthea | PairCorr |
| 0.88 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
Moving against Halozyme Stock
| 0.46 | EVO | Evotec SE ADR Earnings Call Today | PairCorr |
| 0.42 | PCRX | Pacira Pharmaceuticals Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Halozyme Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Halozyme Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Halozyme Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Helen Torley | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [HaloSource Corporation, Halo Labs Inc] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Midcap 400, ARCA Biotechnology, NASDAQ Biotechnology, NASDAQ Composite, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Jakarta Stock Exchange, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Halozyme Therapeutics report their recommendations after researching Halozyme Therapeutics' financial statements, talking to executives and customers, or listening in on Halozyme Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Halozyme Therapeutics. The Halozyme consensus assessment is calculated by taking the average forecast from all of the analysts covering Halozyme Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Halozyme Therapeutics' liquidity, profitability, solvency, and operating efficiency, Halozyme Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in May. Financial strength of Halozyme Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Halozyme Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Halozyme Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Halozyme Therapeutics' financial leverage. It provides some insight into what part of Halozyme Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Halozyme Therapeutics (HALO) is traded on NASDAQ Exchange in USA. It is located in 12390 El Camino Real, San Diego, CA, United States, 92130 and employs 373 people. Halozyme Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.92 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Halozyme Therapeutics's market, we take the total number of its shares issued and multiply it by Halozyme Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Halozyme Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 127.05 M outstanding shares of which 7.89 M shares are currently shorted by private and institutional investors with about 8.17 trading days to cover.
Halozyme Therapeutics currently holds about 209.36 M in cash with 388.57 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52.
Check Halozyme Therapeutics Probability Of Bankruptcy
Ownership AllocationHalozyme Therapeutics secures a total of 127.05 Million outstanding shares. The majority of Halozyme Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Halozyme Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Halozyme Therapeutics. Please pay attention to any change in the institutional holdings of Halozyme Therapeutics as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Halozyme Ownership Details
Halozyme Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Halozyme Therapeutics jumping above the current price in 90 days from now is about 40.13%. The Halozyme Therapeutics probability density function shows the probability of Halozyme Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.2858. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Halozyme Therapeutics will likely underperform. Additionally, halozyme Therapeutics has an alpha of 0.0583, implying that it can generate a 0.0583 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Halozyme Therapeutics to move above the current price in 90 days from now is about 40.13 (This Halozyme Therapeutics probability density function shows the probability of Halozyme Stock to fall within a particular range of prices over 90 days) .
Halozyme Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Halozyme Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Halozyme Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Halozyme Therapeutics' value.| Instituion | Recorded On | Shares | |
| Amvescap Plc. | 2023-12-31 | 2 M | |
| Td Asset Management Inc | 2023-12-31 | 2 M | |
| Northern Trust Corp | 2023-12-31 | 2 M | |
| Thrivent Financial For Lutherans | 2023-12-31 | 1.9 M | |
| Charles Schwab Investment Management Inc | 2023-12-31 | 1.7 M | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 1.6 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2023-12-31 | 1.6 M | |
| Nuveen Asset Management, Llc | 2023-12-31 | 1.5 M | |
| Stephens Inv Mgmt Group Llc | 2023-12-31 | 1.5 M | |
| Blackrock Inc | 2023-12-31 | 18.6 M | |
| Vanguard Group Inc | 2023-12-31 | 13.3 M |
Halozyme Therapeutics Historical Income Statement
Halozyme Therapeutics Income Statement is one of the three primary financial statements used for reporting Halozyme's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Halozyme Therapeutics revenue and expense. Halozyme Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Halozyme Therapeutics' Other Operating Expenses is very stable compared to the past year. As of the 24th of April 2024, Operating Income is likely to grow to about 354.5 M, though Non Operating Income Net Other is likely to grow to (1.4 M). View More FundamentalsHalozyme Stock Against Markets
Picking the right benchmark for Halozyme Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Halozyme Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Halozyme Therapeutics is critical whether you are bullish or bearish towards Halozyme Therapeutics at a given time. Please also check how Halozyme Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Halozyme Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Pair Correlation Now
Pair CorrelationCompare performance and examine fundamental relationship between any two equity instruments |
| All Next | Launch Module |
Halozyme Therapeutics Corporate Directors
Halozyme Therapeutics corporate directors refer to members of a Halozyme Therapeutics board of directors. The board of directors generally takes responsibility for the Halozyme Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Halozyme Therapeutics' board members must vote for the resolution. The Halozyme Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Matthew Posard | Director | Profile | |
| Randal Kirk | Independent Director | Profile | |
| Jeffrey Henderson | Director | Profile | |
| James Daly | Director | Profile |
How to buy Halozyme Stock?
Before investing in Halozyme Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Halozyme Therapeutics. To buy Halozyme Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Halozyme Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Halozyme Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Halozyme Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Halozyme Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Halozyme Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Halozyme Stock please use our How to Invest in Halozyme Therapeutics guide.
Already Invested in Halozyme Therapeutics?
The danger of trading Halozyme Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Halozyme Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Halozyme Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Halozyme Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Halozyme Stock analysis
When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.546 | Earnings Share 2.1 | Revenue Per Share 6.286 | Quarterly Revenue Growth 0.267 | Return On Assets 0.1189 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.